| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL3R; CD123; IL3RX; IL3RY; IL3RAY; hIL-3Ra |
| Entrez GeneID | 3563 |
| clone | 10B8E7 |
| WB Predicted band size | 43.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL3RA (AA: 200-305) expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于IL3RA抗体的3篇参考文献示例(内容为模拟，仅供参考)：
1. **文献名称**：*Targeting IL3RA on blastic plasmacyid dendritic cell neoplasms with chimeric antigen receptor T cells*
**作者**：Kharfan-Dabaja, M.A. 等
**摘要**：该研究报道了利用靶向IL3RA(CD123)的CAR-T细胞治疗浆细胞样树突状细胞肿瘤的临床前结果，证明其能有效诱导肿瘤细胞凋亡并抑制体内肿瘤生长。
2. **文献名称**：*IL3RA as a therapeutic target in acute myeloid leukemia: antibody-drug conjugate development*
**作者**：Smith, C.C. 等
**摘要**：研究开发了一种新型IL3RA抗体药物偶联物(ADC)，通过体外和动物模型验证其对急性髓系白血病(AML)细胞的特异性杀伤作用，并探讨其耐药机制。
3. **文献名称**：*CD123 expression and anti-IL3RA antibody efficacy in systemic lupus erythematosus*
**作者**：Yao, Y. 等
**摘要**：该文献揭示了IL3RA在系统性红斑狼疮(SLE)患者免疫细胞中的异常表达，并证明靶向IL3RA的抗体可缓解小鼠模型中的自身免疫反应。
4. **文献名称**：*Structural insights into IL3RA recognition by a neutralizing antibody for cancer immunotherapy*
**作者**：Lee, J. 等
**摘要**：通过冷冻电镜解析了中和抗体与IL3RA的复合物结构，阐明了其结合表位及抑制IL-3信号通路的分子机制，为优化抗体药物提供依据。
(注：以上文献为示例性内容，实际引用时请核实真实文献信息。)
Interleukin-3 receptor alpha (IL3RA), also known as CD123. is a transmembrane protein that serves as the alpha subunit of the heterodimeric interleukin-3 receptor (IL-3R). It pairs with the beta common chain (βc) to form a functional receptor complex, enabling high-affinity binding of IL-3. a cytokine critical for hematopoiesis and immune regulation. IL3RA is predominantly expressed on hematopoietic cells, including plasmacytoid dendritic cells, basophils, and certain myeloid malignancies. Its dysregulation is implicated in diseases such as acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and autoimmune disorders.
IL3RA antibodies are tools designed to target this receptor, either for diagnostic or therapeutic purposes. In research, they facilitate the identification and isolation of IL3RA-expressing cells via flow cytometry or immunohistochemistry. Therapeutically, anti-IL3RA monoclonal antibodies, antibody-drug conjugates (ADCs), or CAR-T cell therapies exploit IL3RA overexpression on malignant cells to deliver cytotoxic payloads or induce immune-mediated cell death. For example, Tagraxofusp, an IL3RA-targeted ADC, is approved for BPDCN treatment. However, challenges remain, including on-target/off-tumor toxicity due to low IL3RA expression on healthy cells and antigen escape mechanisms in cancers. Ongoing studies aim to refine specificity and efficacy, positioning IL3RA as a promising target in precision oncology.
×
